Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast04: Trastuzumab deruxtecan vs physician's choice in HER2-low unresectable/metastatic breast cancer
2018-003069-33Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival in hormone receptor–positive subjects. Started Jan 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003069-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003069-33.